Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.

Also called NCT04952766

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose other
Phase
Phase 4
Enrolled
  • 196 participants (enrolled count) (from the registry)
Sponsor
Centre Hospitalier Régional d'Orléans (from the registry)
Registry
  • NCT NCT04952766
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04952766. Allocation not applicable; no masking; primary purpose other. Start 2021-03-26 (actual); primary completion 2022-02-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
Acronym
EREVA
Condition
Kidney Transplant
Condition
Myeloma
Condition
Cancer
Condition
Hematologic Malignancy
Condition
Multiple Sclerosis
Condition
Hypergammaglobulinemia
Condition
Malignant Tumor
Condition
Hiv
Condition
Diabetes Type 2
Intervention (Biological)
Biological samples
Lead sponsor
Centre Hospitalier Régional d'Orléans (class: other)

Record details

Record id
cardio:ct-nct04952766
Content hash
674ab26743b3ccaae9013a212226c4e3b08b4ef95d1315d2509ffc18dbba0964